4--[(4-Methylpiperazin-1-yl) methyl]benzoic acid dihydrochloride CAS 106261-49-8 Imatinib Mesylate Yepakati Yakanyanya Kuchena
Commerce Supply Imatinib Mesylate uye Related Intermediates:
Imatinib Mesylate CAS: 220127-57-1
N-(2-Methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine CAS: 152460-09-8
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinea CAS: 152460-10-1
4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride CAS: 106261-49-8
Chemical Name | 4- [(4-Methylpiperazin-1-yl) methyl]benzoic acid dihydrochloride |
Mashoko anoreva zvakafanana | Imatinib Mesylate Pakati |
Nhamba yeCAS | 106261-49-8 |
Nhamba yeCAT | RF-PI229 |
Stock Status | MuStock, Kugadzirwa Kunokwira Kusvika Matani |
Molecular Formula | C13H20Cl2N2O2 |
Molecular Weight | 307.22 |
Melting Point | 305.0~307.0℃ |
Solubility | Soluble mumvura |
Brand | Ruifu Chemical |
Item | Zvinotsanangurwa |
Chitarisiko | Ichena kusvika Kunenge Ichena Hupfu kusvika kuCrystal |
Kuchena / Analysis Method | ≥98.0% (HPLC) |
Kurasika paKuomesa | ≤0.50% |
Residue pamoto | ≤0.50% |
Zvose Zvisina Kuchena | ≤2.0% |
Maximum Single Kusachena | ≤1.0% |
Test Standard | Enterprise Standard |
Usage | Pharmaceutical Pakati peImatinib Mesylate (CAS: 220127-57-1) |
Package: Bhodhoro, Aluminium foil bag, Cardboard dhiramu, 25kg/Drum, kana zvinoenderana nezvinodiwa nemutengi.
Storage Condition:Chengetedza mumidziyo yakavharwa panzvimbo inotonhorera uye yakaoma;Dzivirira kubva kuchiedza, mwando uye tumbuyu.
Shanghai Ruifu Chemical Co., Ltd. ndiyo inotungamira mugadziri uye mutengesi we4--[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride (CAS: 106261-49-8) ine mhando yepamusoro.Itiri yepakati kazhinji mune synthesis yeImatinib Mesylate (CAS: 220127-57-1).Imatinib Mesylate inonzi tyrosine kinase inhibitor, yakanyanya kunyanya kuBCR-ABL, mushonga wemuromo wekurapa varwere vakuru vane Philadelphia chromosome positive chronic myeloid leukemia (CML) muchikamu chepamusoro uye mamwe maitiro e acute lymphoblastic leukemia (ALL), yakakurumidza. chikamu uye chisingaperi chikamu mushure mekukundikana kwe interferon therapy.